DNA repair is established as a programmable determinant of CRISPR-Cas antifungal activity and provide a mechanistic framework for combinatorial targeting strategies, advancing the development of CRISPR-Cas antifungals.
Abstract
Drug-resistant fungal pathogens pose a growing public health threat, causing millions of infections and deaths annually. Limited antifungal drug classes and rising resistance highlight the urgent need for novel therapies. CRISPR-Cas systems offer sequence-specific antimicrobial potential, but their efficacy is influenced by organism-specific DNA repair outcomes. Here, we demonstrate that in Candida albicans, which predominantly relies on homology-directed repair (HDR), both repair template availability and DNA repair enzyme activity critically determine Cas9-induced lethality. By providing Trojan Horse donor DNA repair templates when targeting essential and DNA repair genes, we show that Cas9 lethality can be selectively tuned. Furthermore, multiplexed gRNA targeting to modulate DNA repair capacity reveals strong synergistic interactions when co-targeting HDR components, which is corroborated by enhanced killing in HDR-compromised strains. These results establish DNA repair as a programmable determinant of CRISPR-Cas antifungal activity and provide a mechanistic framework for combinatorial targeting strategies, advancing the development of CRISPR-Cas antifungals. GRAPHICAL ABSTRACT
This review critically examines bacteriophage-based antimicrobials, CRISPR-Cas therapeutic systems, and their emerging integration as CRISPR-armed phages, highlighting their comparative advantages, current limitations, and future potential as promising targeted antimicrobial approach platforms requiring further clinica...
Anjaneyulu Musini, V. Yata, Sarad Pawar Naik Bukke et al.· Molecular Biology Reports· 0 citations
Clinical applicability is limited by issues such off-target effects, PAM sequence restrictions, DNA damage-induced toxicity, and immunological responses to Cas proteins, despite its wide therapeutic potential, but improvements in delivery methods and high-fidelity Cas9 variations are being addressed.
Sanjeyan N., G. G., H. S et al.· International Journal of Bas...· 0 citations
Antimicrobial resistance (AMR) is a growing public health threat, where drug-resistant Candida infections are associated with increased hospital costs, lengths of stay, and high mortality rates. Current diagnostic methods are slow and labor-intensive, causing delays in diagnosis and patient treatment. In this research,...
A. Heathcote, M. Bird, H. Jeong et al.· medRxiv· 0 citations
Four convergent, non-traditional pillars emerged — programmable CRISPR-Cas and CRISPRi genomic tools, monoclonal antibodies and bioconjugates, antimicrobial and anticancer peptides, and stimuli-responsive nanozymes and exosomal carriers — each capable of bypassing classical resistance mechanisms while, at least in prec...
Drug-resistant Staphylococcus aureus remains one of the major clinical challenges in both community and hospital settings. Increasing rates of resistance to conventional antibiotics have prompted the development of alternative therapeutic strategies capable of selectively targeting essential bacterial functions. Nuclei...
R. Ghasemi, Hamid Heidari· Infectious Disease and Thera...· 0 citations
The mechanisms of CRISPR/Cas action and its applications in hematologic malignancies, breast cancer, colorectal cancer, gastric cancer, and lung cancer are explored.
M. Omarov, E. Karacheva, M. M. Arapieva et al.· Сибирский научный медицински...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.